Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: role of calcium overload.
There is increasing evidence that cardiac glycosides act through mechanisms distinct from inhibition of the sodium pump but which may contribute to their cardiac actions. To more fully define differences between agents indicative of multiple sites of action, we studied changes in contractility and action potential (AP) configuration in cat ventricular myocytes produced by six cardiac glycosides (ouabain, ouabagenin, dihydroouabain, actodigin, digoxin, and resibufogenin). AP shortening was observed only with ouabain and actodigin. There was extensive inotropic variability between agents, with some giving full inotropic effects before automaticity occurred whereas others produced minimal inotropy before toxicity. AP shortening was not a result of alterations in calcium current or the inward rectifier potassium current, but correlated with an increase in steady-state outward current (Iss), which was sensitive to KB-R7943, a Na+-Ca2+ exchange (NCX) inhibitor. Interestingly, Iss was observed following exposure to ouabain and dihydroouabain, suggesting that an additional mechanism is operative with dihydroouabain that prevents AP shortening. Further investigation into differences in inotropy between ouabagenin, dihydroouabain and ouabain revealed almost identical responses under AP voltage clamp. Thus all agents appear to act on the sodium pump and thereby secondarily increase the outward reverse mode NCX current, but the extent of AP duration shortening and positive inotropy elicited by each agent is limited by development of their toxic actions. The quantitative differences between cardiac glycosides suggest that mechanisms independent of sodium pump inhibition may result from an altered threshold for calcium overload possibly involving direct or indirect effects on calcium release from the sarcoplasmic reticulum.
Ruch
Stuart R
SR
Department of Medicine, Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, IL 60611, USA.
Nishio
Manabu
M
Wasserstrom
J Andrew
JA
D000200:Action Potentials / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D002118:Calcium / Q000008:administration & dosage* / Q000494:pharmacology; D002301:Cardiac Glycosides / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology; D002415:Cats; D004347:Drug Interactions; D004594:Electrophysiology; D006352:Heart Ventricles / Q000166:cytology; D032342:Muscle Cells / Q000187:drug effects* / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects*; D010042:Ouabain / Q000031:analogs & derivatives* / Q000494:pharmacology
D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; C000977:dihydroouabain; D010042:Ouabain; C008721:ouabagenin; D002118:Calcium